LDV20 vs ORTHONIX: How Two OZNEX Australian Listed Medicines Differ
LDV20 vs ORTHONIX
- Both products: Pure Australia-sponsored OZNEX Australian Listed Medicines, manufactured in Australia to TGA-GMP standards, supplied as 120 capsules (4 × 30-capsule blister packs per box).
- LDV20: AUST L 502251 — cardiovascular / metabolic / hepatic / macronutrient complementary support category. Active ingredients: Policosanol (20 mg per recommended daily dose), Berberine, Milk Thistle (silymarin), Chromium.
- ORTHONIX: AUST L 490670 — bone, joint, cartilage, connective-tissue support category. Active ingredients: Chondroitin, Glucosamine, Boswellia, MSM (methylsulfonylmethane), Hyaluronic Acid.
- Regulator: Therapeutic Goods Administration (TGA); both products listed on the Australian Register of Therapeutic Goods (ARTG).
- Editorial scope: This article compares the two products on regulatory status, ingredient profile and formulation rationale. Scientific references discussed in either column relate to individual ingredients and do not constitute clinical studies conducted on LDV20 or ORTHONIX themselves.
LDV20 vs ORTHONIX: How Two OZNEX Australian Listed Medicines Differ
Editorial Notice
This article has been prepared by the editorial team at Pure Australia for educational purposes.
It compares two Pure Australia–sponsored Australian Listed Medicines — LDV20 (AUST L 502251) and ORTHONIX (AUST L 490670) — at the level of regulatory status, ingredient profile and formulation rationale.
It does not include a customer-experience narrative; readers seeking that format should consult the prior editorial in this series.
Scientific references discussed in either comparison column relate to the individual ingredients and do not represent clinical studies conducted on LDV20 or ORTHONIX themselves.
Both products are Australian Listed Medicines. Always read the label and follow the directions for use.
Consumers reading the OZNEX collection often arrive with one question and leave with another. The first question is usually "what does this product do"; the second is "is this one right for me — and how does it compare with the other one I'm looking at?" This article is structured around the second question, with LDV20 (AUST L 502251) and ORTHONIX (AUST L 490670) as the two medicines being compared.
1 · Regulatory status, side by side
Both LDV20 and ORTHONIX are Australian Listed Medicines — but with different ARTG entries and different listing timelines:
| Field | LDV20 | ORTHONIX |
|---|---|---|
| ARTG entry | AUST L 502251 | AUST L 490670 |
| Sponsor | Pure Australia Pty Ltd | Pure Australia Pty Ltd |
| Brand | OZNEX | OZNEX |
| Manufacturing standard | TGA-GMP | TGA-GMP |
| Pack format | 120 capsules, 4 × 30 | 120 capsules, 4 × 30 |
| Formulation category | Cardiovascular / metabolic / hepatic / macronutrient complementary support | Bone strength, joint comfort and mobility; cartilage and connective-tissue support |
| Number of active ingredients | 4 | 5 |
Consumers can verify either listing directly using the ARTG public visualisation tool or the TGA search portal described in TGA's ARTG search instructions.
2 · What the two products share — sponsor, brand, format and constraints
Every Australian Listed Medicine has the same baseline constraints from the TGA framework. LDV20 and ORTHONIX both sit inside that baseline:
- Same sponsor. Both are sponsored by Pure Australia Pty Ltd.
- Same brand line. Both are sold under the OZNEX brand.
- Same pack format. Both are supplied as 120 capsules in 4 × 30-capsule blister packs.
- Same manufacturing standard. Both must be manufactured in TGA-GMP licensed facilities.
- Same claims ceiling. Both are AUST L products and may only support or maintain healthy physiological function within normal range; neither may represent that it diagnoses, treats, cures or prevents any disease, per the TGA labelling rule.
- Same label verification path. Both can be looked up by AUST L number at the official TGA pages for LDV20 and ORTHONIX.
This shared platform is part of why the two products look coherent on the same OZNEX collection page, but it is also where the comparison has to begin — the shared platform is not the same thing as the shared indication.
3 · Where the two products differ — formulation category
The practical difference between LDV20 and ORTHONIX sits in which body system the formulation is designed around. Both are designed around complementary support for a group of physiological pathways, but the pathways are different:
| Pathway / system | LDV20 | ORTHONIX |
|---|---|---|
| Cardiovascular / lipid balance within normal range | ● (Policosanol) | — |
| Metabolic / glucose within normal range | ● (Berberine) | — |
| Hepatic / antioxidant | ● (Milk Thistle / silymarin) | — |
| Macronutrient metabolism | ● (Chromium) | — |
| Joint comfort / mobility | — | ● (Glucosamine) |
| Cartilage support | — | ● (Chondroitin) |
| Connective tissue / collagen formation | — | ● (Hyaluronic Acid) |
| Mild stiffness / inflammation modulation within normal range | — | ● (Boswellia + MSM) |
| Antioxidant support | ● (silymarin) | ● (Boswellia / listed antioxidants) |
Read down the two columns and the difference becomes immediately visible. LDV20 is designed around cardiovascular, metabolic, hepatic and macronutrient metabolism pathways; ORTHONIX is designed around joint, cartilage and connective-tissue pathways. The two products do not overlap in ingredient-level categories and do not appear to be designed to substitute for one another.
4 · The LDV20 column — four ingredients, one direction
LDV20's formulation has been covered, ingredient by ingredient, in earlier articles of this series — Article 003 (Policosanol), Article 004 (Berberine), the Milk Thistle / silymarin explainer and Article 006 (Chromium). The brief ingredient-level map for reference:
| Ingredient | Pathway focus | Anchor ingredient-level research |
|---|---|---|
| Policosanol (20 mg per recommended daily dose) | Cardiovascular / lipid balance | Sugarcane meta-analysis, 2017 |
| Berberine | Metabolic / glucose | PMC review, 2021 |
| Milk Thistle (silymarin) | Hepatic / antioxidant | StatPearls, 2024 |
| Chromium | Macronutrient metabolism | NIH ODS Fact Sheet |
Each study cited in this column evaluated the individual ingredient on its own. None evaluated LDV20 as a finished product. This separation is deliberate and is described in more detail in Article 002 of this series.
5 · The ORTHONIX column — five ingredients, a different direction
ORTHONIX is a five-ingredient formulation built around bone, joint, cartilage and connective-tissue functions. Per its product page, the active ingredients are Chondroitin, Glucosamine, Boswellia, MSM (methylsulfonylmethane) and Hyaluronic Acid. Published studies on each of these ingredients under research conditions are summarised below; none of these studies evaluated ORTHONIX as a finished product.
| Ingredient | Pathway focus (per ORTHONIX label) | Anchor ingredient-level research |
|---|---|---|
| Glucosamine | Cartilage / joint comfort | NIH ODS Consumer Fact Sheet — Glucosamine & Chondroitin · Clegg et al., NEJM, 2006 (GAIT) · Wandel et al., BMJ, 2010 |
| Chondroitin | Cartilage matrix | NIH ODS Consumer Fact Sheet — Glucosamine & Chondroitin · Clegg et al., NEJM, 2006 |
| Boswellia | Mild stiffness modulation (within normal range) | Boswellia review, 2020 (PMC) |
| MSM (methylsulfonylmethane) | Connective-tissue support | Butawan et al., 2017 |
| Hyaluronic Acid | Connective tissue / collagen formation | Oral-route research is distinct from the more established injectable-route research; see the NIH Office of Dietary Supplements search portal for current reviews. |
The category spread here is on a different axis from LDV20 — bone, cartilage, joint comfort, connective tissue, and mild stiffness modulation within normal range. The ingredient-level evidence base for Glucosamine and Chondroitin is well established and freely accessible at the NIH ODS Consumer Fact Sheet. The evidence base for Boswellia, MSM and oral Hyaluronic Acid is younger, and consumers should expect to see more variable findings for those three.
None of the studies referenced in this column evaluated ORTHONIX itself — they evaluated the individual ingredients under various research conditions.
6 · How a consumer decides which one matches their goal
The simplest way to think about the choice between LDV20 and ORTHONIX is to map it onto the formulation category each product was designed around:
| Read this question… | The closer match in the OZNEX range |
|---|---|
| My primary interest is cardiovascular / metabolic / liver / macronutrient complementary support within normal range. | LDV20 (AUST L 502251) |
| My primary interest is joint comfort, mobility, cartilage and connective-tissue support within normal range. | ORTHONIX (AUST L 490670) |
| My primary interest is immune / antioxidant / propolis-style support. | OZNEX Eucalyptus Propolis 15000 with Zinc |
| My primary interest is sleep / brain / eye support. | OZNEX NYXIS |
If a consumer's goals are mixed across more than one category — say, both cardiovascular and joint comfort — the right next step is to consult the manufacturer's Our Story page, the Pure Australia contact page, and (most importantly) their own qualified healthcare professional, especially if they're pregnant, breastfeeding, on prescription medicines or managing a diagnosed condition.
7 · FAQ
Are LDV20 and ORTHONIX made by the same company?
Yes. Both are Pure Australia Pty Ltd–sponsored OZNEX–brand TGA–listed medicines manufactured in Australia.
Are they the same product?
No. LDV20 (AUST L 502251) and ORTHONIX (AUST L 490670) are distinct ARTG entries with different active ingredient profiles and different formulation categories. LDV20 targets cardiovascular, metabolic, hepatic and macronutrient metabolism complementary support; ORTHONIX targets bone strength, joint comfort, mobility, cartilage and connective-tissue support.
Can the two products be taken together?
Both are AUST L products with their own directions-for-use on the label. This comparison article does not make a recommendation on combined use — that decision is best made against the directions on each individual product and in consultation with a qualified healthcare professional, particularly if the consumer is pregnant, breastfeeding, on prescription medicines or managing a diagnosed condition.
Where do I read the manufacturer's own information?
- LDV20 product page (Korean store)
- LDV20 product page (English store)
- ORTHONIX product page (Korean store)
- ORTHONIX product page (English store)
- LDV20 Official Information Center
- LDV20 FAQ
- OZNEX full range
8 · References
Australian regulators
LDV20 ingredients — published research on individual ingredients
ORTHONIX ingredients — published research on individual ingredients
Pure Australia internal pages referenced in this article
- Pure Australia — Home
- Pure Australia — Korean store
- OZNEX Collection
- LDV20 product page (Korean)
- LDV20 product page (English)
- ORTHONIX product page (Korean)
- ORTHONIX product page (English)
- Eucalyptus Propolis 15000 with Zinc (Korean)
- NYXIS (Korean)
- LDV20 Official Information Center
- LDV20 FAQ
- Our Story
- Contact
- Pure Australia blog index
- Article 001 — LDV20 Policosanol Explainer (20 mg)
- Article 002 — LDV20 Editorial Review
- Article 003 — LDV20 Policosanol Explainer (standalone)
- Article 004 — LDV20 Berberine Explainer
- Article 005 — LDV20 Milk Thistle / Silymarin Explainer
- Article 006 — LDV20 Chromium Explainer
Editorial Disclaimer
This article is published by Pure Australia for educational and informational purposes.
It compares two Australian Listed Medicines — LDV20 (AUST L 502251) and ORTHONIX (AUST L 490670) — on regulatory status, ingredient profile and formulation category.
Scientific references discussed relate to individual ingredients unless otherwise stated and do not represent clinical studies conducted on either product themselves.
Both products are Australian Listed Medicines entered on the Australian Register of Therapeutic Goods (ARTG).
Always read the label and follow the directions for use.
If symptoms persist, worsen, or if you have concerns regarding your health, consult a qualified healthcare professional.